Drug Approval | January 05, 2026
FDA nod to first-ever treatment for deadly post-transplant complication TA-TMA
The decision positions Yartemlea as the first and only approved inhibitor of the lectin pathway of complement
The decision positions Yartemlea as the first and only approved inhibitor of the lectin pathway of complement
Syrma Johari is a globally recognised medical device engineering and manufacturing organisation
Leaders from science, policy, industry, and investment came together in New Delhi to examine how alignment across the biotechnology value chain can turn innovation into outcomes at scale
The resubmission of BLA for MOLBREEVI names Fujifilm as the drug substance manufacturer
The company announced that it has been granted patent covering “Substituted Ethylamine Fused Heterocyclic Mescaline Derivatives.”
The study will run across 18 sites and enroll roughly 200 patients over 24 months
ICC is a highly aggressive liver cancer arising from the intrahepatic biliary epithelium
The Toumai platform, currently the only robotic system with US FDA Study Approval for telesurgery, enabled real-time surgical control with no compromise to patient safety
CIRRUS-HCM, an open-label, multi-part study, evaluates EDG-7500 in patients with obstructive and nonobstructive HCM
The company views ESG reporting as a strategic tool to build trust with clients, investors, regulators, and stakeholders worldwide
Subscribe To Our Newsletter & Stay Updated
